Abstract
HIV (human immunodeficiency virus) is a virus that infects different cell types in the immune system. While different monoclonal antibodies have been identified, because of the antigenic diversity of HIV, defining broad neutralising antibodies (bnAbs) it has been very challenging. Using the 10x Chromium technology partitioning system, we performed single-cell sequencing of the B cell repertoire and analysed a cohort of 48 HIV-negative subjects randomised into 4 groups each receiving a different HIV vaccine regime to investigate the type of antibody response to each of the proteins in the vaccine groups, namely ConM SOSIP, EDC ConM SOSIP, ConS UFO and EDC ConS UFO. We recovered over >300,000 single cells and reconstructed full-length antibody heavy- and light-chain variable regions from individual memory B cells, plasmablasts, naïve B cells and activated B cells as well as retrieved their transcriptome profile to correctly separate the different populations within each individual. We identified seven clonotypes representing functional antibodies against vaccine candidate proteins. We reconstructed their phylogenetic tree and confirmed they were novel antibodies in response to HIV. These were mainly antibodies in response to two of the four protein candidates, namely ConS UFO and EDC ConS UFO.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03816137
Funding Statement
EAVI2020 grant 681137
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB 18/LO/2196 of Imperial College London gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be available upon reasonable request
